These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27251672)

  • 21. Treatment recommendations based on fracture risk status are not consistently provided in osteoporosis guidelines.
    Sale JEM; Gray M; Mancuso D; Inrig T; Boire G; Beaulieu MC; Funnell L; Bogoch E
    Rheumatol Int; 2018 Dec; 38(12):2193-2208. PubMed ID: 30367203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How long should we treat?
    Roux C; Briot K
    Osteoporos Int; 2014 Jun; 25(6):1659-66. PubMed ID: 24668004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Place of bisphosphonates in the primary andsecondary prophylaxis of osteoporotic fractures: the role of parenteral therapy--proposal to modify the standards of treatment].
    Deszczyński J; Rawo T; Petelewicz T
    Chir Narzadow Ruchu Ortop Pol; 2011; 76(4):225-31. PubMed ID: 22235647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutic holidays in osteoporosis: Long-term strategy of treatment with bisphosphonates].
    Moro Álvarez MJ; Neyro JL; Castañeda S
    Med Clin (Barc); 2016 Jan; 146(1):24-9. PubMed ID: 26048545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Update and perspectives of anabolic therapies for osteoporosis].
    Endo I; Matsumoto T
    Clin Calcium; 2012 Mar; 22(3):327-33. PubMed ID: 22370299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Etiopathogenesis and treatment of osteoporosis and fractures in adult males].
    Martínez Díaz-Guerra G; Guadalix Iglesias S; Hawkins Carranza F
    Med Clin (Barc); 2011 Nov; 137(14):656-62. PubMed ID: 21420694
    [No Abstract]   [Full Text] [Related]  

  • 27. [Monitoring bone turnover markers during treatment with the anabolic agent teriparatide; in particular, treatment using daily and weekly subucutaneous injections].
    Miyauchi A
    Clin Calcium; 2012 Mar; 22(3):387-98. PubMed ID: 22370306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for osteoporosis: recommendation statement.
    U.S. Preventive Services Task Force
    Am Fam Physician; 2011 May; 83(10):1197-200. PubMed ID: 21568254
    [No Abstract]   [Full Text] [Related]  

  • 29. Successful knowledge translation intervention in long-term care: final results from the vitamin D and osteoporosis study (ViDOS) pilot cluster randomized controlled trial.
    Kennedy CC; Ioannidis G; Thabane L; Adachi JD; Marr S; Giangregorio LM; Morin SN; Crilly RG; Josse RG; Lohfeld L; Pickard LE; van der Horst ML; Campbell G; Stroud J; Dolovich L; Sawka AM; Jain R; Nash L; Papaioannou A
    Trials; 2015 May; 16():214. PubMed ID: 25962885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Current approach to osteoporosis].
    Hosoi T
    Clin Calcium; 2013 Jan; 23(1):75-82. PubMed ID: 23268305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Osteoporosis: therapy in interface management].
    Mikosch P; Gosch M
    Wien Med Wochenschr; 2013 Oct; 163(19-20):455-61. PubMed ID: 24081748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rethinking osteoporosis: balancing risk and benefit in diagnosis, prevention, and treatment.
    Smith A; Shaw B; Laliberte D; Langston J; Bushardt RL
    JAAPA; 2013 Aug; 26(8):20-7. PubMed ID: 24049936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Management of the patient with a high risk of fracture in clinical practice. Results from a survey of 174 Spanish Rheumatologists (OSTEOPAR project)].
    Casado E; Caamaño M; Sánchez-Bursón J; Salas E; Malouf J; Rentero ML; Herrero-Beaumont G
    Reumatol Clin; 2011; 7(5):305-13. PubMed ID: 21925446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucocorticoid-induced osteoporosis: when and who should we treat?
    Morel G; Biver E; Borg S; Chopin F; Hoppé E; Rajzbaum G
    Joint Bone Spine; 2011 Dec; 78 Suppl 2():S214-7. PubMed ID: 22153674
    [No Abstract]   [Full Text] [Related]  

  • 35. [Diabetes and osteoporosis].
    Ferrari S
    Rev Med Suisse; 2013 Jun; 9(390):1256, 1258-9. PubMed ID: 23821843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Denosumab--a new efficient osteoporosis therapy].
    Rejnmark L; Vestergaard P; Mosekilde L
    Ugeskr Laeger; 2011 Jan; 173(5):346-9. PubMed ID: 21276398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fracture risk associated with chronic use of bisphosphonates: evidence today.
    Charopoulos I; Orme S; Giannoudis PV
    Expert Opin Drug Saf; 2011 Jan; 10(1):67-76. PubMed ID: 21121870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis.
    Laroche M; Livideanu C; Paul C; Cantagrel A
    Am J Med; 2011 Aug; 124(8):776-8. PubMed ID: 21787907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Osteoporosis in the man: broad indication for strontium ranelate].
    MMW Fortschr Med; 2012 Nov; 154(21):86-7. PubMed ID: 23270063
    [No Abstract]   [Full Text] [Related]  

  • 40. [SECOT-GEIOS guidelines in osteoporosis and fragility fracture. An update].
    Etxebarria-Foronda I; Caeiro-Rey JR; Larrainzar-Garijo R; Vaquero-Cervino E; Roca-Ruiz L; Mesa-Ramos M; Merino Pérez J; Carpintero-Benitez P; Fernández Cebrián A; Gil-Garay E
    Rev Esp Cir Ortop Traumatol; 2015; 59(6):373-93. PubMed ID: 26233814
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.